Primary small-cell neuroendocrine carcinoma of the breast: Report of a case
Autor: | Hiroshi Takeyama, Kazumasa Komine, Jison Nagase, Satoki Kinoshita, Susumu Kobayashi, Toshiaki Morikawa, Ken Uchida, Goi Sakamoto, Hirano A, Shigeya Kyoda |
---|---|
Rok vydání: | 2008 |
Předmět: |
Adult
Oncology medicine.medical_specialty medicine.medical_treatment Breast Neoplasms Diagnosis Differential Fatal Outcome Breast cancer Surgical oncology Internal medicine medicine Carcinoma Humans Neoplasm Invasiveness Carcinoma Small Cell Chemotherapy business.industry Biopsy Needle Combination chemotherapy General Medicine medicine.disease Carcinoma Neuroendocrine Docetaxel Tumor progression Female Surgery Ultrasonography Mammary Radiology Differential diagnosis business medicine.drug |
Zdroj: | Surgery Today. 38:734-738 |
ISSN: | 1436-2813 0941-1291 |
DOI: | 10.1007/s00595-007-3716-0 |
Popis: | Primary small-cell neuroendocrine carcinoma of the breast is a rare and aggressive neoplasm without an established treatment protocol because so few cases have been described. We report a case of primary small-cell neuroendocrine carcinoma in a 31-year-old woman. The patient came to our hospital 10 days after consulting another clinic, where a diagnosis of locally advanced breast cancer suitable for neoadjuvant chemotherapy had been made. Core needle biopsy under ultrasonographic guidance revealed invasive carcinoma. The doubling time of the tumor progression was calculated as 12 days based on ultrasonographic measurement. After three cycles of chemotherapeutic regimens consisting of adriamycin plus docetaxel, the disease was judged to be progressive and the patient underwent surgery. Definitive histopathological examination revealed primary small-cell neuroendocrine carcinoma. Local and mediastinal recurrence with multiple liver metastases developed only 5 weeks after surgery. Cisplatin plus irinotecan combination chemotherapy was started; however, the patient died of aggressive recurrent tumor progression 6 months after surgery, in spite of the transient tumor regression achieved by chemotherapy. This case reinforces the importance of an early correct diagnosis and the standardization of a treatment regimen for this very rare tumor. |
Databáze: | OpenAIRE |
Externí odkaz: |